Biotech investors’ plea to Trump, and a busy M&A week - Takeaways - MDSpire

Biotech investors’ plea to Trump, and a busy M&A week

  • By

  • Elaine Chen

  • Adam Feuerstein

  • Allison DeAngelis

  • April 2, 2026

  • 0 min

Share

  • 1

    Biotech investors are advocating for regulatory changes from the FDA to enhance drug approval processes.

  • 2

    Eli Lilly has entered the sleep medicine market following the U.S. approval of its obesity pill.

  • 3

    Recent M&A activity among large pharmaceutical companies indicates a dynamic investment landscape.

  • 4

    An industry-patient coalition has formally requested more regulatory flexibility from President Trump.

  • 5

    The podcast discusses various topics, including the promotion of psychedelic drugs on YouTube.

Original Source(s)

Biotech investors’ plea to Trump, and a busy M&A week

  • by Elaine Chen, Adam Feuerstein, Allison DeAngelis

  • April 2, 2026

Related Content

Understanding the BALANCE Model for GLP-1 Medications in Medicare and Medicaid

The ‘velocity of obesity’ aims to show which nations are slowing an epidemic

Live from JPM 2026, a sit-down with Novo Nordisk’s CEO and VC Bob Nelsen